Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） [Phase 2]
A Phase 2 trial investigating neoadjuvant sintilimab with chemotherapy for resectable non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2022-07-11Clinical Trial Update: An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib [Phase 2]
Open-label Phase 2 trial of sotorasib in KRAS G12C-mutant non-small cell lung cancer with a translational study to identify acquired resista…
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC [Phase 2]
Phase 2 study investigating famitinib in combination with HS-10296 for EGFR-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC [Phase 2]
Phase 2 trial updating a combination of recombinant human endostatin with PD-1 antibody and first-line chemotherapy for driver gene negative…
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression [Phase 2]
Phase 2 trial evaluating HLX07 in nonsquamous non-small cell lung cancer with high EGFR expression (status unknown).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C [Phase 1, Phase 2]
Phase 1/2 study evaluating an EGFR tyrosine kinase inhibitor in combination with EGF receptor pathway targeting in EGFR-mutant non-small cel…
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Navarixin in combination with pembrolizumab in adults with selected advanced/metastatic …
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing M7824 (bintrafusp alfa) to pembrolizumab as first-line treatment in PD-L1-expressing advanced non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC [Phase 1, Phase 2]
Phase 1/2 trial evaluating nivolumab combined with anlotinib as re-challenge therapy in advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Phase II Trial of Continuation Therapy in Advanced NSCLC [Phase 2]
Phase II trial update on continuation therapy for advanced non-small cell lung cancer has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial update for HS-10376 in advanced non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial updating docetaxel with or without PI-88 in stage IIIB/IV non-small cell lung cancer completed.
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial of PI-88 with docetaxel in advanced non-small-cell lung cancer completed.
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE) [Phase 2]
Phase 2 trial update evaluating neoadjuvant furmonertinib with cisplatin/pemetrexed in EGFR-mutated resectable NSCLC (stages IIIA-IIIB).
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in advanced malignancies (termi…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of Sym015 (anti-MET) in advanced solid tumors, including MET-amplified/non-small cell lung cancer, completed with posted res…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing TAB008 to Avastin in EGFR wild-type non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative [Phase 1, Phase 2]
Clinical trial update for Ningetinib (CT053PTSA) plus Gefitinib in stage IIIB/IV non-small cell lung cancer with EGFR mutation and T790M neg…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study of erlotinib hydrochloride combined with onalespib lactate in patients wit…
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer [Phase 2]
Phase 2 trial update of crizotinib in ROS1-translocated lung cancer (EU CROSS) completed.
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer [Phase 3]
Phase III study evaluating almonertinib after chemoradiation in patients with stage III unresectable non-small cell lung cancer is currently…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer [Phase 3]
Phase 3 trial update on neoadjuvant or adjuvant chemotherapy in operable non-small-cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-06-10Clinical Trial Update: A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial update for Envafolimab in stage III non-small cell lung cancer is reported as ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel [Phase 2]
Phase II trial updates sequential consolidation with pembrolizumab followed by nab-paclitaxel in non-small cell lung cancer; study completed…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) [Phase 3]
A Phase 3 trial evaluating pembrolizumab with or without lenvatinib in PD-L1–positive treatment-naïve non-small cell lung cancer has complet…